» Articles » PMID: 25821749

Transition Zone Prostate Specific Antigen Density Improves Prostate Cancer Detection in Iranian Men

Overview
Journal Nephrourol Mon
Publisher Brieflands
Specialty Nephrology
Date 2015 Mar 31
PMID 25821749
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Prostate specific antigen (PSA) as a tumor marker has extensively changed the diagnosis of prostate cancer (PCa). With the advent of PSA, the majority of patients are diagnosed with nonpalpable early stage PCa. However, PSA lacks specificity and many patients undergo unnecessary biopsies due to an elevated serum PSA level.

Objectives: This study aimed to assess the sensitivity and specificity of transition zone PSA density (TZPSAD) in detection of PCa.

Patients And Methods: This study was performed on 1712 men underwent trans-rectal ultrasound guided prostate biopsy in our institution between March 2008 and March 2013. A total of 1120 men with PSA < 20 ng/mL and normal digital rectal exam were selected for evaluation. Transition zone PSA density was calculated in all patients and the receiver operating characteristic (ROC) curve was used to analyze the accuracy of TZPSAD for the diagnosis of PCa.

Results: Among 1120 men who were eligible for enrolment, prostate cancer was detected in 265 patients. Mean serum PSA levels were 9.7 ± 4.3 ng/mL and 8.5 ± 3.7 ng/mL in patients with and without PCa, respectively (P < 0.001). Mean value for TZPSAD was 1.18 ± 1.19 ng/mL/mL in patients with PCa, whereas it was 0.55 ± 0.84 ng/mL in men without cancer (P < 0.001). Optimal cut-off value for TZPSAD was 0.32 ng/mL. At this cut-off value, the sensitivity and specificity values for TZPSAD were 85% and 45%, respectively. Applying the TZPSAD for PCa screening decreased 50% of unnecessary biopsies.

Conclusions: Using TZPSAD as an adjunct to PSA may improve the specificity of PSA in the diagnosis of PCa and decrease the number of unnecessary prostatic biopsies in Iranian men with serum PSA level < 20 ng/mL.

Citing Articles

Zonal adjusted PSA density improves prostate cancer detection rates compared with PSA in Taiwanese males with PSA < 20 ng/ml.

Chang T, Lin W, Tsai W, Chiang P, Chen M, Tseng J BMC Urol. 2020; 20(1):151.

PMID: 33028274 PMC: 7542736. DOI: 10.1186/s12894-020-00717-z.


The roles of MRI-based prostate volume and associated zone-adjusted prostate-specific antigen concentrations in predicting prostate cancer and high-risk prostate cancer.

Zheng S, Jiang S, Chen Z, Huang Z, Shi W, Liu B PLoS One. 2019; 14(11):e0218645.

PMID: 31743339 PMC: 6863612. DOI: 10.1371/journal.pone.0218645.


Peripheral zone volume ratio (PZ-ratio) is relevant with biopsy results and can increase the accuracy of current diagnostic modality.

Chang Y, Chen R, Yang Q, Gao X, Xu C, Lu J Oncotarget. 2017; 8(21):34836-34843.

PMID: 28422738 PMC: 5471015. DOI: 10.18632/oncotarget.16753.

References
1.
Sung D, Bum Cho S, Kim Y, Oh Y, Lee N, Kim J . Comparison of prostate-specific antigen adjusted for transition zone volume versus prostate-specific antigen density in predicting prostate cancer by transrectal ultrasonography. J Ultrasound Med. 2004; 23(5):615-22. DOI: 10.7863/jum.2004.23.5.615. View

2.
Zheng X, Xie L, Wang Y, Ding W, Yang K, Shen H . The use of prostate specific antigen (PSA) density in detecting prostate cancer in Chinese men with PSA levels of 4-10 ng/mL. J Cancer Res Clin Oncol. 2008; 134(11):1207-10. DOI: 10.1007/s00432-008-0400-8. View

3.
Chen C, Wang S, Li J, Cheng C, Yang C, Chen W . PSA density as a better predictor of prostate cancer than percent-free PSA in a repeat biopsy. J Chin Med Assoc. 2011; 74(12):552-5. DOI: 10.1016/j.jcma.2011.10.004. View

4.
Lam J, Cheung Y, Benson M, Goluboff E . Comparison of the predictive accuracy of serum prostate specific antigen levels and prostate specific antigen density in the detection of prostate cancer in Hispanic-American and white men. J Urol. 2003; 170(2 Pt 1):451-6. DOI: 10.1097/01.ju.0000074707.49775.46. View

5.
Matsuda T, Saika K . Comparison of time trends in prostate cancer incidence (1973 1997) in East Asia, Europe and USA, from Cancer Incidence in Five Continents Vols IV VIII. Jpn J Clin Oncol. 2007; 37(7):556-7. DOI: 10.1093/jjco/hym100. View